United States
Print page content Print
Increase text size Decrease text size
Text Size

Canine Influenza Vaccine, H3N2, Killed Virus*

VIRUSES KEEP EVOLVING. ZOETIS KEEPS INNOVATING.

Canine influenza virus (CIV) was already an emerging concern within the ​veterinary community when the highly contagious CIV type H3N2 was identified in the U.S. in March 2015 and quickly spread across more than 30 states.1

In November 2015, the U.S. Department of Agriculture (USDA) granted Zoetis a conditional license to supply veterinarians with Canine Influenza Vaccine, H3N2, Killed Virus* to help address outbreaks.

About Canine Influenza Virus

As you may know, CIV is highly contagious.2 Direct contact and droplets from sneezing or coughing spread CIV directly from dog to dog. Droplets also contaminate surfaces, food, bowls and other objects, increasing the potential for further infections.2,3 Environments such as dog shows, dog parks, pet day care centers and the like are particularly risky.

CIV can be difficult to diagnose and potentially difficult to treat. Clinical signs—including coughing, sneezing, nasal and ocular discharge, and anorexia—sometimes don’t emerge until after the majority of virus shedding has occurred. Plus, samples collected during clinical exam may not identify CIV.4

In the contiguous United States from 2006 to 2014, CIV H3N8 was reported in 36 states. From March 2015 to July 2016, CIV H3N2 was found in 30 states.1

All dogs can be at risk of contracting CIV—regardless of breed, age, sex or health status.2 In some cases, CIV symptoms can be severe. Prevention remains the best course of action.

Notifications

Receive Notifications and Updates About This Vaccine

About Canine Influenza Vaccine, H3N2, Killed Virus*

Canine Influenza Vaccine, H3N2, Killed Virus*, a vaccine on a trusted platform, helps you protect your canine patients from outbreaks.

Strain: Canine influenza virus H3N2, A/canine/Illinois/12191/2015

  • Conditionally licensed by the USDA
  • Aids in controlling disease associated with CIV H3N2

Indication: For use in healthy dogs ≥ 8 weeks of age

  • 2 doses, 3 weeks apart
  • Recommended annual revaccination with a single dose
  • Availability: 25 x 1-dose packages

*This product license is conditional. Efficacy and potency test studies are in progress.

More Information:
Learn about our CIV H3N8 vaccine, VANGUARD® CIV »

1 Canine influenza virus monitoring effort: testing summary 5/23/2015 - 7/11/2016. Cornell University Animal Health Diagnostic Center. https://ahdc.vet.cornell.edu/docs/CIV_Monitoring_2016-07-11.pdf. Accessed August 9, 2016.

2 Crawford C, Spindel M. Canine influenza. In: Miller L, Hurley K, eds. Infectious Disease Management in Animal Shelters. Ames, IA: Wiley-Blackwell; 2009:173-180.

3 Canine influenza: pet owners’ guide. American Veterinary Medical Association. https://www.avma.org/public/PetCare/Pages/CanineInfluenza.aspx. Accessed August 9, 2016.

4 Dubovi EJ, Njaa BL. Canine influenza. Vet Clin North Am Sm Anim Pract. 2008;38(4):827-835.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2016 Zoetis Services LLC. All rights reserved. SAB-00187